Evaxion A/S (NASDAQ:EVAX) Stock Rating Upgraded by Wall Street Zen

Evaxion A/S (NASDAQ:EVAX) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday.

EVAX has been the topic of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Evaxion A/S in a report on Monday, March 9th. Lake Street Capital cut their price target on Evaxion A/S from $11.00 to $9.00 and set a “buy” rating for the company in a report on Monday, March 9th. Maxim Group assumed coverage on Evaxion A/S in a research report on Thursday, February 19th. They issued a “buy” rating and a $10.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evaxion A/S in a research note on Friday, January 9th. Finally, JonesTrading assumed coverage on Evaxion A/S in a research report on Tuesday. They set a “buy” rating and a $10.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Evaxion A/S has an average rating of “Moderate Buy” and an average target price of $11.00.

Evaxion A/S Stock Up 1.9%

Evaxion A/S stock opened at $4.26 on Friday. Evaxion A/S has a fifty-two week low of $1.20 and a fifty-two week high of $12.15. The firm has a market capitalization of $35.53 million, a price-to-earnings ratio of -3.23 and a beta of 0.28. The stock’s fifty day moving average is $3.81 and its two-hundred day moving average is $4.63. The company has a debt-to-equity ratio of 0.41, a quick ratio of 5.85 and a current ratio of 5.85.

Evaxion A/S (NASDAQ:EVAX) last released its quarterly earnings data on Thursday, March 5th. The company reported $0.30 EPS for the quarter. Analysts predict that Evaxion A/S will post -0.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Evaxion A/S during the fourth quarter worth $38,000. Wesbanco Bank Inc. acquired a new position in Evaxion A/S in the fourth quarter valued at $48,000. Finally, SmartHarvest Portfolios LLC acquired a new position in Evaxion A/S in the fourth quarter valued at $72,000. Hedge funds and other institutional investors own 11.04% of the company’s stock.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.